

## 4Q25 Activity Report – Net Operating Performance Improving

28 July 2025

Anagenics Limited (ASX: AN1, “Anagenics” or the “Company”) today provides an update on activities during the quarter ended 30 June 2025 (“4Q25”).

During 4Q25, the Company achieved a significant improvement in operating cash flows, driven by the previously detailed business restructuring, which delivered an operating cash flow of \$ 132,000 for the quarter.

The Company has completed the business restructuring process, which began in early October 2024, and achieved significant improvements in overall financial performance compared to the last financial year.

Following a successful launch in May, Flouf Factor Growth Tonic continued the strong performance of Bouf Haircare products. Based on sales revenue since launch the brand is on track to exceed \$9 million in sales in its first year, ahead of initial expectations. YSB is also evaluating further growth opportunities, including potential expansion into international markets, which is expected to generate higher royalty fee receipts for the Company in FY2026.

The Company is in dialogue with Roquefort Therapeutics' midkine antibody licencing and will continue to provide any additional information in accordance with its continuous disclosure obligations. Shareholders interested in the progress of Roquefort's efforts to progress a transaction involving Lyramid are referred to its website at <https://www.roquefortplc.com>. Anagenics notes that as at the date of this announcement Roquefort has not completed a transaction and has extended the date of completion for the transaction until 31 August 2025.

During the quarter ended 30 June 2025, the Company didn't make any payments to or to associates of related parties of the entity included in Appendix 4C for the quarter ended 30 June 2025.

The Directors of Anagenics believe the Company has sufficient funds on hand to support its normal level of net Operating Cash Flow requirements over the next two quarters, such that the Company does not require additional equity funding for this purpose.

The Company continues to seek value-accretive opportunities in line with its stated strategy and objectives.

*‘This announcement was authorised by the Board of Anagenics Limited.*

### For further information, please contact:

Sandy Beard  
Chair, Anagenics Limited  
P: 0412 308 263  
E: [sandy@xvgroup.com.au](mailto:sandy@xvgroup.com.au)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ANAGENICS LIMITED

ABN

69 111 304 119

Quarter ended ("current quarter")

30 Jun 2025

Consolidated statement of cash flows	Current quarter (3 months) \$A'000	Year to date (12 months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,297	5,762
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(568)	(4,181)
(c) advertising and marketing	(50)	(422)
(d) leased assets	-	-
(e) staff and director costs	(348)	(1,757)
(f) administration and corporate costs	(191)	(1,036)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(8)	(40)
1.6 Income taxes (paid) / refunded	-	-
1.7 Government grants and tax incentives	-	98
1.8 Other	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>132</b>	<b>(1,576)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities (net)	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter (3 months) \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities (net)	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	790
3.6	Repayment of borrowings & leasing	(102)	(445)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(102)</b>	<b>345</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	<b>367</b>	<b>1,624</b>
4.2	Net cash from / (used in) operating activities (item 1.9 above)	132	(1,576)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter (3 months) \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(102)	345
4.5	Effect of movement in exchange rates on cash held	(2)	2
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>395</b>	<b>395</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	253	253
5.2	Call deposits	142	142
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>395</b>	<b>395</b>

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1	Loan facilities - Unsecured	790	565
7.2	Credit standby arrangements	-	-
7.3	Loan facilities - Secured	1,000	-
7.4	<b>Total financing facilities</b>	<b>1,790</b>	<b>565</b>
7.5	<b>Unused financing facilities available at quarter end</b>		<b>1,225</b>
7.6	<p>Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</p> <p>7.1a - Loan facilities from Shopify a multinational e-commerce company.</p> <ul style="list-style-type: none"> <li>• Unsecured loan facility of \$340,000</li> <li>• Sales proceeds to repay the loan and drawdown of loan within the approved facility limit post repayment of loan by the Company</li> <li>• Loan facility will expire and due for repayment in full of any outstanding balance on 17 April 2026</li> <li>• Interest at 10% per annum is payable on loan balance</li> </ul> <p>7.1b – Short term loan from Hancock and Gore Limited (ASX: HNG)</p> <ul style="list-style-type: none"> <li>• Interest free unsecured loan facility of \$200,000</li> <li>• Loan facility will be repaid by 30 December 2025 or on completion of capital raising whichever is earlier.</li> </ul> <p>7.1c - Short term loan from Sandy Bead</p> <ul style="list-style-type: none"> <li>• Interest free unsecured loan facility of \$150,000</li> <li>• Loan facility will be repaid by 30 December 2025 or on completion of capital raising whichever is earlier.</li> </ul> <p>7.1d - Short term loan from Con Scrinis</p> <ul style="list-style-type: none"> <li>• Interest free unsecured loan facility of \$100,000</li> <li>• Loan facility will be repaid by 30 December 2025 or on completion of capital raising whichever is earlier.</li> </ul> <p>7.3 – Loan facilities Secured</p> <ul style="list-style-type: none"> <li>• Boom Capital Pty Ltd will provide a loan facility of \$1,000,000, secured with a fixed charge over all current assets and future debtors of BLC Cosmetics Pty Ltd, a wholly-owned subsidiary of the Company.</li> <li>• Boom Capital will provide 85% of approved debtors, and a facility fee of 1% of the gross debtor's value is payable.</li> <li>• Interest at 10% per annum is payable on a loan drawn by the Company.</li> <li>• Payments received from debtors will be applied to repay the loan drawn by the Company.</li> <li>• Boom Capital will provide a secured loan facility for two years, expiring on 1 March 2027.</li> </ul>		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	132
8.2	Cash and cash equivalents at quarter end (item 4.6)	395
8.3	Unused finance facilities available at quarter end (item 7.5)	1,225
8.4	Total available funding (item 8.2 + item 8.3)	1,620
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 July 2025.....

Authorised by: **Board of Directors – Anagenics Limited**.....  
 (Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.